Emifenac Uses

Rating: 2.5 - 4 review(s)
sponsored
Did you have any side effects with this medicine?

What is Emifenac?

Emifenac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and other symptoms of arthritis of the joints (eg, osteoarthritis), such as inflammation, swelling, stiffness, and joint pain. However, Emifenac does not cure osteoarthritis and will help you only as long as you continue to use it.

Emifenac topical 3% gel is also used to treat actinic keratosis, a skin problem that may become cancerous if not treated. The exact way that topical Emifenac helps this condition is unknown.

Emifenac topical solution is used to treat pain and swelling caused by osteoarthritis of the knees.

Emifenac topical patch is used to treat acute pain caused by minor strains, sprains, and contusions (bruises).

Emifenac is available only with your doctor's prescription.

Emifenac indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Intramuscular

Renal colic

Adult: As Emifenac Na: 75 mg, may repeat once after 30 min if needed. Max: 150 mg/day. Max period: 2 days.

Intramuscular

Bursitis, Pain and inflammation associated with musculoskeletal and joint disorders, Rheumatoid arthritis, Sprains, Strains, Tendinitis, Acute gout, Dysmenorrhoea

Adult: As Emifenac Na: 75 mg once daily, injected into the gluteal muscle, may increase to 75 mg bid in severe conditions. Max period: 2 days.

Intravenous

Postoperative pain

Adult: As Emifenac Na: 75 mg infusion in glucose 5% or NaCl 0.9% (previously buffered w/ Na bicarbonate) given over 30-120 min or as bolus inj, may repeat after 4-6 hr if necessary. Max period: 2 days.

Intravenous

Prophylaxis of postoperative pain

Adult: As Emifenac Na: Initially, 25-50 mg infusion given after surgery over 15-60 min followed by 5 mg/hr. Alternatively, initial dose may be given as bolus inj over 5-60 sec followed by additional inj, may repeat after 4-6 hr if necessary. Max: 150 mg/day. Max period: 2 days.

Ophthalmic

Postoperative ocular inflammation

Adult: As Emifenac Na (0.1% soln): Instill into the appropriate eye 4 times daily starting 24 hr after surgery for up to 28 days.

Ophthalmic

Inflammation and discomfort after strabismus surgery

Adult: As Emifenac Na (0.1% soln): Instill 1 drop 4 times daily for the 1st wk; then tid in the 2nd wk, bid in the 3rd wk, and as required for the 4th wk.

Ophthalmic

Pain and discomfort after radial keratotomy

Adult: As Emifenac Na (0.1% soln): Instill 1 drop before surgery followed by 1 drop immediately after surgery, and then 1 drop 4 times daily for up to 2 days.

Ophthalmic

Pain after accidental trauma

Adult: As Emifenac Na (0.1% soln): Instill 1 drop 4 times daily for up to 2 days.

Ophthalmic

Control of inflammation after argon laser trabeculoplasty

Adult: As Emifenac Na (0.1% soln): Instill 1 drop 4 times during the 2 hr before procedure followed by 1 drop 4 times daily, up to 7 days after procedure.

Ophthalmic

Prophylaxis of intra-operative miosis

Adult: As Emifenac Na (0.1% soln): Instill into appropriate eye 4 times w/in 2 hr before surgery.

Ophthalmic

Post-photorefractive keratectomy pain

Adult: As Emifenac Na (0.1% soln): Instill into the affected eye twice, an hr before surgery, then 1 drop twice at 5-min intervals immediately after surgery, then every 2-5 hr while awake for up to 24 hr.

Ophthalmic

Seasonal allergic conjunctivitis

Adult: As Emifenac Na (0.1% soln): Instill 1 drop before surgery followed by 1 drop immediately after surgery, and then 1 drop 4 times daily for up to 2 days.

Oral

Bursitis, Pain and inflammation associated with musculoskeletal and joint disorders, Rheumatoid arthritis, Sprains, Strains, Tendinitis, Acute gout, Dysmenorrhoea

Adult: As Emifenac Na: 75-150 mg/day in divided doses. Max: 150 mg/day.

Oral

Migraine

Adult: As Emifenac K: Initially, 50 mg taken at the 1st sign of an attack, an additional dose of 50 mg may be taken after 2 hr if symptoms persist. If needed, further doses of 50 mg may be taken 4-6 hrly. Max: 200 mg/day.

Rectal

Acute gout, Bursitis, Dysmenorrhoea, Pain and inflammation associated with musculoskeletal and joint disorders, Rheumatoid arthritis, Sprains, Strains, Tendinitis

Adult: As Emifenac Na: 100 mg once daily.

Topical/Cutaneous

Actinic keratoses

Adult: As Emifenac Na (3% gel): Apply bid for 60-90 days.

Topical/Cutaneous

Osteoarthritis

Adult: As Emifenac Na (1.6% soln): Apply in small amounts (20 or 40 drops) onto affected area 4 times daily. As Na: (1% gel): Apply to the affected area 4 times daily. Max: 32 g/day over the affected area.

Topical/Cutaneous

Local symptomatic relief of pain and inflammation

Adult: As Emifenac Na (1% gel): Apply onto affected area 3 or 4 times daily.

Transdermal

Acute pain

Adult: Sprains, strains, contusions: 1 patch bid.

How should I use Emifenac?

Use Emifenac solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • Emifenac solution comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Emifenac solution refilled.
  • Do not apply Emifenac solution to infected skin; open wounds; or red, swollen, or peeling skin.
  • Wash your hands immediately before and after using Emifenac solution.
  • Wash the affected area and dry completely before using Emifenac solution.
  • To apply Emifenac solution, dispense 10 drops at a time onto the knee or into your hand. Spread Emifenac solution evenly around the front, back, and sides of the knee. Repeat until you have used the whole dose.
  • Be sure that you cover your entire knee with your dose of Emifenac solution. Do not use more than the recommended amount.
  • Do not apply sunscreens, cosmetics, insect repellants, other topical medicines, or any other substance to the treated area until it is completely dry.
  • Do not put on clothes over the treated area until it is completely dry.
  • Do not wrap, bandage, or apply heat to the treated area.
  • Let the treated skin dry before touching it or letting it touch anyone else's skin.
  • Do not shower, bathe, or wash the treated area for at least 30 minutes after you use Emifenac solution.
  • If you miss a dose of Emifenac solution, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Emifenac solution.

Uses of Emifenac in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Emifenac is used to relieve pain from various conditions. This form of Emifenac is used to treat migraine headaches. Emifenac is a nonsteroidal anti-inflammatory drug (NSAID). It works by blocking your body's production of certain natural substances that cause inflammation. This effect helps to decrease swelling, pain, or fever.

OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.

This medication may also be used to treat gout attacks.

How to use Emifenac

Read the Medication Guide provided by your pharmacist before you start taking Emifenac and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

Take this medication by mouth as directed by your doctor. Empty the contents of one packet into a cup containing 1 to 2 ounces (30 to 60 milliliters) of water. Mix well and drink all of it right away. Do not mix with any liquid other than water. If stomach upset occurs while taking this medication, take it with food, milk, or an antacid. However, if you take this medication with a meal high in fat, it may not work as well.

There are different brands and forms of this medication available. Because different forms do not have the same effects at equal strengths, do not switch forms of Emifenac unless your doctor tells you to.

To reduce your risk of stomach bleeding and other side effects, take this medication at the lowest effective dose. Do not increase your dose or take it more often than prescribed.

Pain medications work best if they are used as the first signs of pain occur. If you wait until the pain has worsened, the medication may not work as well.

Tell your doctor if your condition persists or worsens.

Emifenac description

sponsored

Emifenac potassium is potassium-o-[(2,6-dichlorophenyl)-amino]-phenyl-acetate.

Emifenac resinate is [o-[(2, 6-dichlorophenyl)-amino]-phenyl-acetate resinate.

Each mL of oral drops contains Diclofenac resinate equivalent to Emifenac potassium 15 mg (0.5 mg/drop).

Excipients/Inactive Ingredients: Tablet: Core: Magnesium stearate, povidone, anhydrous colloidal silica, sodium starch glycollate, maize starch, calcium phosphate. Sugar-Coat: Microcrystalline cellulose, polyethylene glycol 8000, red iron oxide (E172) and titanium dioxide (E171) (dispersed Anstead), povidone, talc, sucrose. Polish: Polyethylene glycol 8000, sucrose.

Oral Drops:

Hydrogenated castor oil, liquid paraffin, saccharin sodium, tutti-frutti 503314 T flavour (contains vanillin), copolymer of acrylic and methacrylic acid with divinylbenzene and ethylvinylbenzene (Zerolite 236 SRC 48).

Emifenac dosage

General Dosing Instructions

Carefully consider the potential benefits and risks of Emifenac and other treatment options before deciding to use Emifenac. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.

The effectiveness of Emifenac when taken with food has not been studied in clinical studies. Taking Emifenac with food may cause a reduction in effectiveness compared to taking Emifenac on an empty stomach.

Acute Pain

For management of mild to moderate acute pain, the dosage is 18 mg or 35 mg orally three times daily.

Osteoarthritis Pain

For management of osteoarthritis pain, the dosage is 35 mg orally three times daily.

Dosage Adjustments In Patients With Hepatic Impairment

Patients with hepatic disease may require reduced doses of Emifenac compared to patients with normal hepatic function. As with other Emifenac products, start treatment at the lowest dose. If efficacy is not achieved with the lowest dose, discontinue use.

Non-Interchangeability With Other Formulations Of Emifenac

Emifenac capsules are not interchangeable with other formulations of oral Emifenac even if the milligram strength is the same. Emifenac capsules contain Emifenac free acid whereas other Emifenac products contain a salt of Emifenac, i.e., Emifenac potassium or sodium. A 35 mg dose of Emifenac is approximately equal to 37.6 mg of sodium Emifenac or 39.5 mg of potassium Emifenac. Therefore, do not substitute similar dosing strengths of other Emifenac products without taking this into consideration.

How supplied

Dosage Forms And Strengths

Emifenac (Emifenac) capsules: 18 mg - blue body and light green cap (imprinted IP-203 on the body and 18 mg on the cap in white ink).

Emifenac (Emifenac) capsules: 35 mg - blue body and green cap (imprinted IP-204 on the body and 35 mg on the cap in white ink).

Storage And Handling

Emifenac (Emifenac) capsules are supplied as:

  • 18 mg - blue body and light green cap (imprinted IP-203 on the body and 18 mg on the cap in white ink)

NDC (42211-203-23), Bottles of 30 capsules

NDC (42211-203-29), Bottles of 90 capsules

  • 35 mg - blue body and green cap (imprinted IP-204 on the body and 35 mg on the cap in white ink)

NDC (42211-204-23), Bottles of 30 capsules

NDC (42211-204-29), Bottles of 90 capsules

Storage

Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).

Store in the original container and keep the bottle tightly closed to protect from moisture. Dispense in a tight container if package is subdivided.

Manufactured (under license from iCeutica Pty Ltd) for and Distributed by: Iroko Pharmaceuticals, LLC, One Kew Place, 150 Rouse Boulevard, Philadelphia, PA 19112. Revised: May 2016

Emifenac interactions

See also:
What other drugs will affect Emifenac?

sponsored

Aspirin: Concomitant administration of Emifenac and aspirin is not recommended because Emifenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels and AUC values.

Anticoagulants: While studies have not shown Emifenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs. Because prostaglandins play an important role in hemostasis and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including Emifenac and warfarin, requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.

Digoxin, Methotrexate, Cyclosporine: Emifenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs. Ingestion of Emifenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine's nephrotoxicity. Patients who begin taking Emifenac or who increase their Emifenac dose or any other NSAID while taking digoxin, methotrexate or cyclosporine may develop toxicity characteristics for these drugs. They should be observed closely, particularly if renal function is impaired. In the case of digoxin, serum levels should be monitored.

Lithium: Emifenac decreases lithium renal clearance and increases lithium plasma levels. In patients taking Emifenac and lithium concomitantly, lithium toxicity may develop.

Oral Hypoglycemics:

Emifenac does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic agents. There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of Emifenac that necessitated changes in the doses of such agents. Both hypo- and hyperglycemic effects have been reported. A direct causal relationship has not been established, but physicians should consider the possibility that Emifenac may alter a diabetic patient's response to insulin or oral hypoglycemic agents.

Diuretics: Emifenac and other NSAIDs can inhibit the activity of diuretics. Concomitant treatment with potassium-sparing diuretics may be associated with increased serum potassium levels.

Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline or digitoxin did not significantly affect the peak levels and AUC values of Emifenac. Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of Emifenac therapy.

Emifenac side effects

See also:
What are the possible side effects of Emifenac?

Fluid Retention and Edema: Fluid retention and edema have been observed in some patients taking Emifenac. Therefore, as with other NSAIDs, Emifenac should be used with caution in patients with history of cardiac decompensation, hypertension or other conditions predisposing to fluid retention.

Hematological Effects: Anemia is sometimes seen in patients receiving Emifenac or other NSAIDs. This may be due to fluid retention, GI blood loss or an incompletely described effect upon erythropoiesis.

Renal Effects: As a class, NSAIDs have been associated with renal papillary necrosis and other abnormal renal pathology in long-term administration to animals. In patients treated with Emifenac, rare cases of interstitial nephritis and papillary necrosis have been reported. A second form of renal toxicity, generally associated with NSAIDs, is seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supported role in the maintenance of renal perfusion. In these patients, administration of an NSAID results in a dose-dependent decrease in prostaglandin synthesis and secondarily, in a reduction of renal blood flow, which may precipitate over the renal failure. Patients at greater risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and the elderly.

Porphyria: The use of Emifenac in patients with hepatic porphyria should be avoided.

Aseptic Meningitis: As with other NSAIDs, aseptic meningitis with fever and coma has been observed in rare occasions in patients on Emifenac therapy. Although it is probably more likely to occur in patients with systemic lupus erythematosus and related connective tissue diseases, it has been reported in patients who do not have an underlying chronic disease. If signs or symptoms of meningitis develop in a patient on Emifenac, the possibility of it being related to Emifenac should be considered.

There may be pain and occasionally tissue damage at the site of injection when given IM.

Emifenac contraindications

See also:
What is the most important information I should know about Emifenac?

Hypersensitivity to Emifenac or to any of the excipients of Emifenac.

Active gastric or intestinal ulcer, bleeding or perforation.

Last trimester of pregnancy.

Hepatic, renal and severe cardiac failure.

Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid and/or other drugs with prostaglandin-synthetase inhibitory activity.

Treatment of peri-operative pain in setting of coronary artery bypass graft (CABG) surgery.

The use of high dose Emifenac (150 mg/day) for >4 weeks is contraindicated in patients with established cardiovascular disease (congestive heart failure, established ischemic heart disease, peripheral arterial disease) or uncontrolled hypertension.

Established Cardiovascular Disease or Significant Cardiovascular Risk Factors: The use of high dose Emifenac (150mg/day) for >4 weeks is contraindicated in patients with established cardiovascular disease (congestive heart failure, established ischemic heart disease, peripheral arterial disease) or uncontrolled hypertension. If Emifenac treatment is needed, patients with established cardiovascular disease, uncontrolled hypertension or significant cardiovascular risk factors (eg, hypertension, hyperlipidaemia, diabetes mellitus and smoking) should be treated only after careful consideration and at doses ≤100 mg daily if the treatment is for >4 weeks. As the cardiovascular risks of Emifenac may increase with dose and duration of exposure, Emifenac should always be prescribed at the lowest effective daily dose and for the shortest duration possible.

Renal Impairment: Emifenac is contraindicated in patients with renal failure. No specific studies have been carried out in patients with renal impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering Emifenac to patients with mild to moderate renal impairment.

Hepatic Impairment: Emifenac is contraindicated in patients with hepatic failure. No specific studies have been carried out in patients with hepatic impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering Emifenac to patients with mild to moderate hepatic impairment.



Active ingredient matches for Emifenac:

Diclofenac in Bahrain, Oman.

Diclofenac Sodium


List of Emifenac substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
EMFLAM GEL topical gel 1.16 % w/w x 30g (Merck)
Enractin-D Trypsin 48 mg, bromelain 90mg, rutoside trihydrate 100mg, diclofenac 50 mg. EC-TAB / 10 (Molekule)$ 2.46
Enractin-D Trypsin 48 mg, bromelain 90mg, rutoside trihydrate 100mg, diclofenac 50 mg. EC-TAB / 10 (Molekule)$ 2.46
ENRACTIN-D enteric-coated tab 10's (Molekule)$ 2.46
Enzoflam Gel Diclofenac 1.16 % w/w, Linseedoil 3 % w/w, Methylsalicylate12 % w/w, Menthol 5.5 % w/w. GEL / 30g (Alkem (Bergen))$ 0.73
30g (Alkem (Bergen))$ 0.73
ENZOFLAM GEL topical gel 30g (Alkem (Bergen))$ 0.73
Enzomac Plus Trypsin 48 mg, bromelain 90mg, rutoside 100 mg, diclofenac 50 mg. TAB / 10 (Macleods (Gencare))$ 2.54
ENZOMAC PLUS TABLET 1 strip / 10 tablets each (Macleods (Gencare))$ 3.06
ENZOMAC PLUS tab 10's (Macleods (Gencare))$ 2.79
Enzomac Plus Tablet (Macleods (Gencare))$ 0.31
Enzovexx - TAB / 10 (Zuventus)$ 0.95
10's (Zuventus)$ 0.95
ENZOVEXX tab 10's (Zuventus)$ 0.95
Erase-D Diclofenac sodium 50 mg, Serratiopeptidase 10 mg. TAB / 10 (Stalwart)$ 0.63
10's (Stalwart)$ 0.63
ERASE-D tab 10's (Stalwart)$ 0.63
Erdon Gel 1 % x 10 g
Erdon Gel 1 % x 20 g
Erdon gel 1 tube 10 g
Erdon gel 1 tube 20 g
Erdon gel 10 mg/1 g x 1 tube 10 g
Erdon gel 10 mg/1 g x 1 tube 20 g
Erdon-100 TR 100 mg x 10 x 10's
ESGIPYRIN - DS Injection / 25mg per ml / 5x3ml units (Nicholas Piramal (Sarabhai Piramal))$ 0.46
ESGIPYRIN AQ 75 MG INJECTION 1 vial / 1 ML injection each (Abbott India Ltd)$ 0.29
Esgipyrin AQ 75mg Injection (Abbott India Ltd)$ 0.29
Esgipyrin DS 25mg/ml INJ / 5x3ml (Sarabhai piramal)$ 0.44
Injectable; Injection; Diclofenac Sodium 25 mg / ml (Sarabhai piramal)
ESGIPYRIN-AQ inj 75 mg x 1ml (AHPL)$ 0.29
Esgipyrin-DS 25mg/ml INJ / 3ml (AHPL)$ 0.12
25 mg x 1 mL x 3ml (AHPL)$ 0.12

References

  1. DailyMed. "DICLOFENAC EPOLAMINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "diclofenac". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "diclofenac". http://www.drugbank.ca/drugs/DB00586 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Emifenac are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Emifenac. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

1 consumer reported useful

Was the Emifenac drug useful in terms of decreasing the symptom or the disease?
According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
Users%
Useful1
100.0%


1 consumer reported price estimates

Was the price you paid to purchase the drug reasonable? Did you feel it was expensive?
The below mentioned numbers have been reported by ndrugs.com website users about whether the Emifenac drug is expensive or inexpensive. There is a mixed opinion among users. The rating about the cost of the drug depends on factors like which brand drug the patient purchased, how effective it was for the price paid, the country or place the drug is marketed, and the economic condition of the patient. The users who feel the drug is expensive can look for an alternative brand drug or a generic drug to save the cost.
Users%
Not expensive1
100.0%


9 consumers reported time for results

To what extent do I have to use Emifenac before I begin to see changes in my health conditions?
As part of the reports released by ndrugs.com website users, it takes 1 day and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Emifenac. To get the time effectiveness of using Emifenac drug by other patients, please click here.
Users%
1 day3
33.3%
3 days3
33.3%
1 month1
11.1%
> 3 month1
11.1%
2 days1
11.1%


20 consumers reported age

Users%
30-459
45.0%
16-299
45.0%
46-602
10.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 18 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2021 ndrugs.com All Rights Reserved